THERAPY DOSSIER · th-1d14a0e0cbcb

Pulp-capping material containing fluocinolone acetonide (PCFA)

Drug · Glucocorticoid receptor agonist (AGONIST); topical/intravitreal corticosteroid

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Glucocorticoid receptor agonist (AGONIST); topical/intravitreal corticosteroid
Target: Glucocorticoid receptor (NR3C1, CHEMBL2034)
Injury models: Other
Reported indication: Not recorded
First approval: 1963
Development stage: Not recorded
ChEMBL record: CHEMBL989 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Fluocinolone acetonide; Synalar; Iluvien; Retisert; Yutiq
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00472966 ↗PHASE4completed

Sequential Therapy With Fluocinolone Acetonide/HQ/Tretinoin (TriLuma) + Glycolic Acid Peels for Melasma

Melasma

Enrolment: 20 · Results not recorded

NCT00695318 ↗PHASE2terminated

Fluocinolone Acetonide Intravitreal Insert vs Sham in Bilateral Geographic Atrophy Due to AMD

Age-Related Macular Degeneration

Enrolment: 17 · Results not recorded

NCT06932848 ↗NArecruiting

Curcumin Nanogels vs 0.1% Fluocinolone Acetonide Oral Paste in Erosive Oral Lichen Planus

Oral Lichen Planus

Enrolment: 30 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25649295 ↗2015Reported benefit

Response of inflamed pulps of rat molars after capping with pulp-capping material containing fluocinolone acetonide.

RatOtherWistarMalen = 60 maxillary molars, n=10 per group across six groupsDirect pulp capping, sealed with Fuji II LC glass ionomer48 h after pulp exposure

Model: Mechanically exposed maxillary molar dental pulp left open to the oral environment for 48 h to induce pulpitis

At 8 days acute inflammation was present in 40% of PCFA samples versus 60% for mineral trioxide aggregate and 80% for Dycal, a significant reduction versus Dycal. At 30 days hard tissue formation occurred in 100% of PCFA samples versus 63% and 78%, although between-group differences at 30 days were…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…